PROFESSOR JAN MÜLLER-BRAND, M.D.

Professor Müller-Brand was born and educated in Prague, Czechoslovakia and later studied Medicine at the University of Basel, Switzerland. After graduation he specialized extensively in Nuclear Medicine, and developed a distinguished international career. In 1999 Professor Müller-Brand was appointed Full Professor of Nuclear Medicine, University Hospital Basel.

Professor Müller-Brand has hundreds of scholarly publications to his credit. A short but representative list is below.

Walter MA, Müller-Brand J, Müller B. Radiopeptide Therapy with [99Yttrium-DOTA]-TOC in Metastasized Gastrinomas: First Results of a Phase II Clinical Trial. Langenbecks Arch Surg 2006 In Print

Frilling A, Weber F, Saner F, Bockisch A, Hofmann M, Mueller-Brand J, Broelsch C.E. Treatment with 90Y- and 177Lu-DOTATOC in patients with metastatic neuroendocrine tumors. Surgery. 2006;140(6):968-77.

Forrer F, Waldherr C, Maecke HR, Mueller-Brand J. Targeted radionuclidetherapy with 90Y-DOTATOC in patients with neuroendocrine tumors. Anticancer Res. 2006;26(1B):703-7.

Forrer F, Uusijarvi H, Storch D, Maecke HR, Mueller-Brand J. Treatment with 177Lu-DOTATOC of patients with relapse of neuroendocrine tumors after treatment with 90Y-DOTATOC. J Nucl Med. 2005;46(8):1310-6.

Kwekkeboom DJ, Mueller-Brand J, Paganelli G, Anthony LB, Pauwels S, Kvols LK, O'dorisio TM, Valkema R, Bodei L, Chinol M, Maecke HR, Krenning EP. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J Nucl Med. 2005;46 Suppl 1:62S-6S. Review.

Otte A, Mueller-Brand J, Dellas S, Nitzsche EU, Herrmann R, Maecke HR. Yttrium-90-labelled somatostatin-analogue for cancer treatment. Lancet. 1998;351(9100):417-418.

back to list of speakers for Toronto 2009 conference